What we do

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.


Testimonials


Omixon Blog

Diversity of MHC Genes in the 1000 Genomes Dataset

Authors: Tünde Vágó, Péter Tóth, Tim Hague, Szilveszter Juhos Introduction: The 1000 Genomes Project (1KG) was the first large-scale sequencing project to obtain comparable whole genome sequences from diverse human populations. Previously we validated our HLA typing method using these datasets for Class-II …more

By kriszta.katona 0 comments

Omixon Celebrates a Successful EFI 2015

EFI 2015, Success for All We had a tremendous experience last week in the amazingly picturesque city of Geneva Switzerland – the backdrop for EFI 2015, facilitated by Prof. Jean-Marie Tiercy and Dr. Jean Villard and their team of professional …more

By kriszta.katona 0 comments